MCM
PLX icon

MAI Capital Management’s Protalix BioTherapeutics PLX Stock Holding History

MAI Capital Management’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-29
Closed -$63 – 4012
2026
Q1 		$63 Buy
+29
New +$72 ﹤0.01% 4830

Other funds holding PLX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SWP
Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

MAI Capital Management's PLX Position: Q2 2026 in Review

MAI Capital Management sold out of Protalix BioTherapeutics (PLX) in Q2 2026, closing a stake of 29 shares — an estimated $63 sold.

MAI Capital Management first reported a position in PLX in Q1 2026 and held it in 1 quarter. The position peaked at $63 in Q1 2026. 102 funds tracked by Wall St. Rank hold PLX as of Q2 2026.

  • MAI Capital Management reported no remaining Protalix BioTherapeutics position as of Q2 2026 after selling out during the quarter.
  • MAI Capital Management sold 29 Protalix BioTherapeutics shares in Q2 2026, an estimated $63.
  • MAI Capital Management first reported a position in Protalix BioTherapeutics in Q1 2026 and held it in 1 quarter.
  • MAI Capital Management's Protalix BioTherapeutics position peaked at $63 in Q1 2026.
  • 102 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.